{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Diabetes", "Dyslipidemia", "Gluconeogenesis", "Glycolysis", "Rutaecarpine"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32536591", "DateCompleted": {"Year": "2020", "Month": "08", "Day": "10"}, "DateRevised": {"Year": "2020", "Month": "08", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "06", "Day": "09"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jphs.2020.04.008", "S1347-8613(20)30057-8"], "Journal": {"ISSN": "1347-8648", "JournalIssue": {"Volume": "143", "Issue": "4", "PubDate": {"Year": "2020", "Month": "Aug"}}, "Title": "Journal of pharmacological sciences", "ISOAbbreviation": "J Pharmacol Sci"}, "ArticleTitle": "Rutaecarpine exhibits anti-diabetic potential in high fat diet-multiple low dose streptozotocin induced type 2 diabetic mice and in\u00a0vitro by modulating hepatic glucose homeostasis.", "Pagination": {"StartPage": "307", "EndPage": "314", "MedlinePgn": "307-314"}, "Abstract": {"AbstractText": ["Rutaecarpine, an indolopyridoquinazoline alkaloid, attracted attentions because of possessing various biological activities. The objective of this study was to investigate the effect of rutaecarpine on glucose and lipid metabolism in high fat diet-multiple low dose streptozotocin induced type 2 diabetic (HFD-db) mice and to understand the mechanism of action. HFD-db mice showed impaired glucose metabolism and lipid profile. Oral administration of rutaecarpine reduced the blood glucose levels, decreased blood hemoglobin A1c (HbA1c) levels, improved glucose tolerance and restored insulin sensitivity in HFD-db mice. Rutaecarpine also decreased body weight gain, water intake and visceral fat gain in HFD-db mice. Total cholesterol, triglycerides, very low density lipoprotein and low density lipoprotein were reduced and high density lipoprotein level was augmented in rutaecarpine treated HFD-db mice. Rutaecarpine also reduced the elevated levels of serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, urea and creatinine in HFD-db mice. Rutaecarpine significantly promoted the rate of glucose consumption, glucose uptake and glycolysis in C2C12 myotubes. Western blotting results showed that rutaecarpine augmented p-GSK-3\u03b2 and p-AMPK expression, and suppressed G6Pase expression in HepG2 cells. These results suggest that rutaecarpine might be having therapeutic importance to fight against type 2 diabetes mellitus associated with dyslipidemia."], "CopyrightInformation": "Copyright \u00a9 2020 The Authors. Production and hosting by Elsevier B.V. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Jawaharlal Nehru Institute of Medical Science, Porompat, Imphal East, 795005, Manipur, India."}], "LastName": "Surbala", "ForeName": "Laishram", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants and Horticulture Resources Division, Institute of Bioresources and Sustainable Development, Takyelpat, Imphal West, 795001, Manipur, India."}], "LastName": "Singh", "ForeName": "Chingakham Brajakishor", "Initials": "CB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Jawaharlal Nehru Institute of Medical Science, Porompat, Imphal East, 795005, Manipur, India."}], "LastName": "Devi", "ForeName": "Rajkumari Vidyabati", "Initials": "RV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Jawaharlal Nehru Institute of Medical Science, Porompat, Imphal East, 795005, Manipur, India. Electronic address: oinamj55@gmail.com."}], "LastName": "Singh", "ForeName": "Oinam Joychandra", "Initials": "OJ"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Japan", "MedlineTA": "J Pharmacol Sci", "NlmUniqueID": "101167001", "ISSNLinking": "1347-8613"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Indole Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "8XZV289PRY", "NameOfSubstance": "rutecarpine"}, {"RegistryNumber": "IY9XDZ35W2", "NameOfSubstance": "Glucose"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy", "etiology"], "DescriptorName": "Diabetes Mellitus, Experimental"}, {"QualifierName": ["drug therapy", "etiology"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Diet, High-Fat"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glucose"}, {"QualifierName": ["drug effects"], "DescriptorName": "Homeostasis"}, {"QualifierName": [], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Indole Alkaloids"}, {"QualifierName": ["metabolism"], "DescriptorName": "Liver"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Quinazolines"}], "CoiStatement": "Declaration of Competing Interest None."}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2019", "Month": "2", "Day": "26"}, {"Year": "2020", "Month": "4", "Day": "23"}, {"Year": "2020", "Month": "4", "Day": "27"}, {"Year": "2020", "Month": "6", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "16", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32536591", "10.1016/j.jphs.2020.04.008", "S1347-8613(20)30057-8"]}}]}